Ignite Creation Date:
2025-12-24 @ 6:25 PM
Ignite Modification Date:
2026-02-22 @ 2:45 PM
Study NCT ID:
NCT04285268
Status:
WITHDRAWN
Last Update Posted:
2020-06-16
First Post:
2020-02-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sponsor:
Rutgers, The State University of New Jersey
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | High Grade B-Cell Lymphoma, Not Otherwise Specified | View |
| None | Recurrent Burkitt Lymphoma | View |
| None | Recurrent Diffuse Large B-Cell Lymphoma | View |
| None | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or … | View |
| None | Refractory Burkitt Lymphoma | View |
| None | Refractory Diffuse Large B-Cell Lymphoma | View |
| None | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or … | View |
Keywords: